Valuing health outcomes is a fundamental concern in health economics. This article considers a measure of health outcomes: the Quality Adjusted Life Year (QALY). The QALY has been used extensively for two main reasons: (1) it arguably values health outcomes in a more acceptable metric than money...

The last decade has shown a concerted effort in the UK to find ways of reducing coronary heart disease (CHD), culminating in the recent government target of a 30% reduction in the rates in people under the age of 65 years to be achieved between 1988 and 2000 by modification of the main risk...

The influence of private health insurance (PHI) and gynaecologists' demand for leisure in determining a caesarean section (CS) delivery is examined. A database collected in January 2002 is exploited which contains records on women who attended the second largest private hospital in Greece. A...

This paper identifies and analyses a number of outstanding regulatory aspects in the completion of the European pharmaceutical single market. It discusses pricing and competition in pharmaceuticals in the aftermath of the 3 Frankfurt Roundtables and their results. It analyses the environment for...

Traditionally, US teaching hospitals have subsidised research by charging higher costs for treatment; however, this approach is being challenged. The growth of managed-care organisations, concerned about maximising profits, has led many to argue that clinical research will be damaged, whether by...

We argue that the dread of Genetically Modified (GM) food is an expression of the individual's demand for information as a self-protective action. This study empirically examines the determinants of the demand for information on Genetically Modified Food and tests whether this demand is jointly...